Subcutaneous immunotherapy for allergic rhinoconjunctivitis, allergic asthma, and prevention of allergic diseases

Allergens and Allergen Immunotherapy, Fourth Edition

Volumn , Issue , 2008, Pages 343-358

  Malling, Hans Jørgen ^a   Bousquet, Jean ^b  

^a Rigshospitalet   (Denmark)

^b UNIV MONTPELLIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN;

ANIMAL; ASTHMA; CONJUNCTIVITIS; DESENSITIZATION; HUMAN; HYPERSENSITIVITY; IMMUNOLOGY; REVIEW; RHINITIS; SUBCUTANEOUS DRUG ADMINISTRATION;

ALLERGENS; ANIMALS; ASTHMA; CONJUNCTIVITIS; DESENSITIZATION, IMMUNOLOGIC; HUMANS; HYPERSENSITIVITY; INJECTIONS, SUBCUTANEOUS; RHINITIS;

EID: 58149470280     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (77)

1. Bauchau V, Durham SR. Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur Respir J 2004; 24: 758-764.
2. Masoli M, Fabian D, Holt S, et al. Global Initiative for Asthma (GINA) Program. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004; 59: 469-478.
3. Bousquet J, Van Cauvenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001; 108: S147-S334.
4. Vignola AM, Chanez P, Godard P, et al. Relationships between rhinitis and asthma. Allergy 1998; 53(9): 833-839.
5. Braunstahl GJ, Kleinjan A, Overbeek SE, et al. Segmental bronchial provocation induced nasal inflammation in allergic rhinitis patients. Am J Respir Crit Care Med 2000; 161: 2051-2057.
6. Linna O, Kokkonen J, Lukin M. A 10-year prognosis for childhood allergic rhinitis. Acta Paediatr 1992; 81: 100-102.
7. Settipane RJ, Hagy GW, Settipane GA. Long-term risk factors for developing asthma and allergic rhinitis: a 23-year follow-up study of college students. Allergy Proc 1994; 15: 21-25.
8. Madonini E, Briatico Vangosa G, et al. Seasonal increase of bronchial reactivity in allergic rhinitis. J Allergy Clin Immunol 1987; 79: 358-363.
9. Braman SS, Barrows AA, DeCotiis BA, et al. Airway hyperresponsiveness in allergic rhinitis. A risk factor for asthma. Chest 1987; 91: 671-674.
10. Anto JM, Sunyer J. Thunderstorms: a risk factor for asthma attacks (editorial, comment). Thorax 1997; 52: 669-670.
11. Knox RB. Grass pollen, thunderstorms and asthma. Clin Exp Allergy 1993; 23: 354-359.
12. Sotomayor H, Badier M, Vervloet D, et al. Seasonal increase of carbachol airway responsiveness in patients allergic to grass pollen: reversal by corticosteroids. Am Rev Respir Dis 1984; 130: 56-58.
13. Platts-Mills TA. The role of allergens in the induction of asthma. Curr Allergy Asthma Rep 2002; 2: 175-180.
14. Vignola AM, Gagliardo R, Siena A, et al. Airway remodeling in the pathogenesis of asthma. Curr Allergy Asthma Rep 2001; 1: 108-115.
15. Ten Hacken NH, Postma DS, Timens W. Airway remodeling and long-term decline in lung function in asthma. Curr Opin Pulm Med 2003; 9: 9-14.
16. Viggnola AM, Paganin F, Capieu L, et al. Airway remodelling assessed by sputum and highresolution computed tomography in asthma and COPD. Eur Respir J 2004; 24: 910-917.
17. Bousquet J, Hejjaoui A, Michel FB. Specific immunotherapy in asthma. J Allergy Clin Immunol 1990; 86: 292-305.
18. Halken S, Host A, Niklassen U, et al. Effect of mattress and pillow encasings on children with asthma and house dust mite allergy. J Allergy Clin Immunol 2003; 111: 169-176.
19. Sheikh A, Hurwitz B, Shehata Y. House dust mite avoidance measures for perennial allergic rhinitis. Cochrane Database Syst Rev 2007; (1): CD001563 (review).
20. Malling H-J, Weeke B. EAACI Immunotherapy position papers. Allergy 1993; 48(suppl 14): 9-35.
21. Bousquet J, Lockey RF, Malling H-J, eds. WHO Position Paper. Allergen immunotherapy: therapeutic vaccines for allergic diseases. Allergy 1998; 53(suppl 44): 1-42.
22. Jacobsen L. Preventive allergy treatment as part of allergy disease management. J Investig Allergol Clin Immunol 1997; 7: 367-368.
23. Jutel M, Jaeger L, Suck R, et al. Allergen-specific immunotherapy with recombinant grass pollen allergens. J Allergy Clin Immunol 2005; 116: 608-613.
24. Frew AJ, Powell RJ, Corrigan CJ, et al. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006; 117: 319-325.
25. Ciprandi G, Buscaglia S, Pesce G, et al. Minimal persistent inflammation is present at mucosal level in patients with asymptomatic rhinitis and mite allergy. J Allergy Clin Immunol 1995; 96: 971-979.
26. Malling H-J. Immunotherapy as an effective tool in allergy treatment. Allergy 1998; 53: 461-472.
27. Canonica GW, Baena-Cagnani CE, Bousquet J, et al. Recommendations for standardization of clinical trials with allergen specific immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce. Allergy 2007; 62: 317-324.
28. Wilson AM, O ' Byrne PM, Parameswaran K. Leukotriene receptor antagonists for allergic rhinitis: a systematic review and meta-analysis. Am J Med 2004; 116: 338-344.
29. Osterballe O. Immunotherapy in hay fever with two major allergens 19, 25 and partially purified extract of timothy grass pollen: a controlled double blind stud. In vivo variables, season 1. Allergy 1980; 35: 473-489.
30. Rak S, Heinrich C, Jacobsen L, et al. A double-blinded, comparative study of the effects of short preseasonal specific immunotherapy and topical steroids in patients with allergic rhinoconjunctivitis and asthma. J Allergy Clin Immunol 2001; 108: 921-928.
31. Bousquet J, Calvayrac P, Guerin B, et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract: 1. In vivo and in vitro parameters after a short course of treatment. J Allergy Clin Immunol 1985; 76: 734-744.
32. Blumberga G, Groes L, Haugaard L, et al. Steroid-sparing effect of subcutaneous SQ-standardised specific immunotherapy in moderate and severe house dust mite allergic asthmatics. Allergy 2006; 61: 843-848.
33. Haugaard L, Dahl R, Jacobsen L. A controlled dose response study of immunotherapy with standardized, partially purified extract of house dust mite: clinical efficacy and side effects. J Allergy Clin Immunol 1993; 91: 709-722.
34. Bousquet J, Hejjaoui A, Clauzel AM, et al. Specific immunotherapy with a standardized Dermatophagoides pteronyssinus extract. II. Prediction of efficacy of immunotherapy. J Allergy Clin Immunol 1988; 82: 971-977.
35. Haugaard L, Dahl R. Immunotherapy in patients allergic to cat and dog dander. I. Clinical results. Allergy 1992; 47: 249-254.
36. Alvarez-Cuesta E, Cuesta-Herranz J, Puyana-Ruiz J, et al. Monoclonal antibody-standardized cat extract immunotherapy: risk-benefit effects from a double-blind placebo study. J Allergy Clin Immuno1 1994; 93: 556-566.
37. Varney V, Edwards J, Tabbah K, et al. Clinical efficacy of specific immunotherapy to cat dander: a double-blind placebo-controlled trial. Clin Exp Allergy 1997; 27: 860-867.
38. Valovirta E, Koivikko A, Vanto T, et al. Immunotherapy in allergy to dog: a double-blind clinical study. Ann Allergy 1984; 53: 85-88.
39. Salvaggio J, Aukrust L. Postgraduate course presentations: mold-induced asthma. J Allergy Clin Immunol 1981; 68: 327-346.
40. Malling HJ, Dreborg S, Weeke B. Diagnosis and immunotherapy of mould allergy. V. Clinical efficacy and side effects of immunotherapy with Cladosporium herbarum. Allergy 1986; 41: 507-519.
41. Horst M, Hejjaoui A, Horst V, et al. Double-blind, placebo-controlled rush immunotherapy with a standardized Alternaria extract. J Allergy Clin Immunol 1990; 85: 460-472.
42. Dreborg S, Agrell B, Foucard T, et al. A double-blind, multicenter immunotherapy trial in children, using a purified and standardized Cladosporium herbarum preparation. I. Clinical results. Allergy 1986; 41: 131-140.
43. Malling H-J. Bacterial vaccines: anything but placebo. Allergy 2000; 55: 214-218.
44. Adkinson N Jr., Eggleston PA, Eney D, et al. A controlled trial of immunotherapy for asthma in allergic children. N Engl J Med 1997; 336: 324-331.
45. Alvarez-Cuesta E, Bousquet J, Canonica GW, et al. Standards for practical allergen-specific immunotherapy. Allergy 2006; 61(suppl 82): 1-20.
46. Li JT, Lockey RF, Bernstein IL, et al. Allergen immunotherapy: a practice parameter. Ann Allergy Asthma Immunol 2003; 90: 1-40.
47. Abramson MJ, Puy RM, Weiner JM. Allergen immunotherapy for asthma. Cochrane Database Syst Rev 2003; (4): CD001186 (review).
48. Malling H-J. Quality and clinical efficacy of allergen mixtures. Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M 2006; 95: 253-257.
49. Calderon MA, Alves B, Jacobson M, et al. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev 2007; (1): CD001936. DOI: 10.1002/14651858.CD001936.pub2.
50. Shekelle PG, Woolf SH, Eccles M, et al. Clinical guidelines: developing guidelines. Br Med J 1999; 318: 593-596.
51. Durham SR, Walker SM, Varga EM, et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999; 341: 468-475.
52. Varney VA, Gaga M, Frew AJ, et al. Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs. Br Med J 1991; 302: 265-269.
53. Eng PA, Reinhold M, Gnehm HPE. Long-term efficacy of preseasonal grass pollen immunotherapy in children. Allergy 2002; 57: 306-312.
54. Eng PA, Borer-Reinhold M, Heijnen IA, et al. Twelve-year follow-up after discontinuation of preseasonal grass pollen immunotherapy in childhood. Allergy 2006; 61: 198-201.
55. Cools M, Van Bever HP, Weyler JJ, et al. Long-term effects of specific immunotherapy, administered during childhood, in asthmatic patients allergic to either house-dust mite or to both house-dust mite and grass pollen. Allergy 2000; 55: 69-73.
56. Malling H-J. Minimising the risks of allergen-specific injection immunotherapy. Drug Saf 2000; 23: 323-332.
57. Bousquet J, Chanez P, Lacoste JY, et al. Asthma: a disease remodeling the airways. Allergy 1992; 47: 3-11.
58. Juniper EF, Guyatt GH, Griffith LE, et al. Interpretation of rhinoconjunctivitis quality of life questionnaire data. J Allergy Clin Immunol 1996; 98: 843-845.
59. Strachan DP, Butland BK, Anderson HR. Incidence and prognosis of asthma and wheezing illness from early childhood to age 33 in a national British cohort. Br Med J 1996; 312: 1195-1199.
60. Sly RM. Managed care-the key to quality of management of asthma. Ann Allergy 1996; 76: 161-163.
61. Bousquet J, Chanez P, Lacoste JY, et al. Asthma: a disease remodeling the airways. Allergy 1992; 47: 3-11.
62. Peat JK, Woolcook AJ, Cullen K. Rate of decline of lung function in subjects with asthma. Eur J Respir Dis 1987; 70: 171-179.
63. Tabar AI, Garcia BE, Rodriguez A, et al. A prospective safety-monitoring study of immunotherapy with biologically standardized extracts. Allergy 1993; 48: 450-453.
64. Rugose FV, Passalacqua G, Gambardella R, et al. Nonfatal systemic reactions to subcutaneous immunotherapy: a 10-year experience. Invest Allergol Clin Immunol 1997; 7: 151-154.
65. Alessandro F, Vincenzo ZG, Marco S, et al. Compliance with pharmacologic prophylaxis and therapy in bronchial asthma. Ann Allergy 1994; 73: 135-140.
66. Yeung M, O’Connor SA, Parry DT, et al. Compliance with prescribed drug therapy in asthma. Respir Med 1994; 88: 31-35.
67. Bronsky WA, Dockhorn RJ, Meltzer EO, et al. Fluticasone propionate aqueous nasal spray compared with terfenadine tablets in the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol 1996; 97: 915-921.
68. Balda BR, Wolf H, Baumgarten C, et al. Tree-pollen allergy is efficiently treated by short-term immunotherapy (STI) with seven preseasonal injections of molecular standardized allergens. Allergy 1998; 53: 740-748.
69. Klimek L, Wolf H, Mewes T, et al. The effect of short-term immunotherapy with molecular standardized grass and rye allergens on eosinophil cationic protein and tryptase in nasal secretions. J Allergy Clin Immunol 1999; 103: 47-53.
70. Des Roches A, Paradis L, Knani J, et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. V. Duration of efficacy of immunotherapy after its cessation. Allergy 1996; 51: 430-433.
71. Hedlin G, Heilborn H, Lilja G, et al. Long-term follow-up of patients treated with a three-year course of cat or dog immunotherapy. J Allergy Clin Immunol 1995; 96: 879-885.
72. Cohn JR, Pizzi A. Determinants of patient compliance with allergen immunotherapy. J Allergy Clin Immunol 1993; 91: 734-737.
73. Purello-D’Ambrosio F, Gangemi S, Merendino RA, et al. Prevention of new sensitizations in monosensitized subjects submitted to specific immunotherapy or not. A retrospective study. Clin Exp Allergy 2001; 31: 1295-1302.
74. Pajno GB, Barberio G, de Luca Fr, et al. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin Exp Allergy 2001; 31: 1392-1397.
75. Mö ller C, Dreborg S, Ferdousi HA, et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 2002; 109: 251-256.
76. Niggemann B, Jacobsen L, Dreborg S, et al. Five year follow-up on the PAT-study: specific immunotherapy and long-term prevention of asthma in children. Allergy 2006; 61: 855-859.
77. Jacobsen L, Niggemann B, Dreborg S et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy 2007; 62: 943-948.